Lung Cancer Clinical Trials in North Carolina

Showing 401-420 of 802 trials

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529

This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.

Non Small Cell Lung CancerStage I Lung CancerStage Ib Lung Carcinoma+3 more

Wake Forest University Health Sciences20 participantsStarted Aug 2019

Winston-Salem, North Carolina, United States

UNKNOWN57 miles

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Lung Cancer

Hummingbird Diagnostics2,000 participantsStarted Oct 2023

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 157 miles

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more

MacroGenics277 participantsStarted Aug 2017

Gilbert, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Lung Cancer Trials in Other Cities

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Prospective Clinicogenomic Program

A Study of PRT2527 in Participants With Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in North Carolina